Product image of Keytruda (Pembrolizumab) supplied by GNH India

Keytruda

Active Ingredient:
Pembrolizumab
Origin:
EU

Keytruda (Pembrolizumab)

Pembrolizumab, the active ingredient in Keytruda, is a monoclonal antibody presented as an injection solution for intravenous infusion for the treatment of various advanced solid tumors and Hodgkin lymphoma. It works by targeting the PD‑1 pathway to enhance the immune system’s ability to fight cancer.

GNH India supplies Keytruda as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures quality compliance and reliable cold‑chain logistics for global distribution.

Manufacturer / TM Owner

Merck Sharp & Dohme B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Keytruda (pembrolizumab) is a PD‑1 inhibitor used in several solid‑tumor and hematologic cancer pathways.

  • Melanoma: improves overall survival in patients with unresectable or metastatic disease.
  • Non‑small cell lung cancer: extends progression‑free survival in advanced cases.
  • Head and neck squamous cell carcinoma: enhances response rates in recurrent or metastatic settings.
  • Classical Hodgkin lymphoma: achieves durable remission in relapsed or refractory patients.
  • Urothelial carcinoma: increases overall survival in metastatic disease.
  • MSI‑high/dMMR solid tumors: provides benefit across tumor types with high microsatellite instability.

How It Works

  • Pembrolizumab binds to the programmed death‑1 (PD‑1) receptor on T cells, blocking its interaction with the ligands PD‑L1 and PD‑L2. This interruption releases the inhibitory checkpoint, allowing T cells to recognize and attack tumor cells more effectively, thereby augmenting the anti‑tumor immune response.

Side Effects

Pembrolizumab may cause a range of immune‑related adverse reactions.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Rash: mild to moderate skin eruptions.
  • Pruritus: itching without visible rash.
  • Diarrhea: loose stools, sometimes requiring management.
  • Nausea: feeling of sickness, may be transient.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pneumonitis: inflammation of lung tissue that can impair breathing.
  • Colitis: severe inflammation of the colon leading to diarrhea.
  • Hepatitis: liver inflammation with elevated enzymes.
  • Endocrinopathies: thyroiditis, adrenal insufficiency, or hypophysitis.
  • Nephritis: kidney inflammation affecting function.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

When using Keytruda, clinicians should observe several safety precautions.

  • Monitor for immune‑related adverse events: assess organ function regularly.
  • Baseline screening: evaluate liver, lung, and endocrine status before treatment.
  • Avoid live vaccines: immunosuppression may increase infection risk.
  • Pregnancy considerations: potential fetal risk; discuss benefits vs risks with a specialist.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Pembrolizumab can interact with other therapies that affect immune function.

Major Interactions (Avoid)

  • Concurrent use with other immune checkpoint inhibitors: may increase toxicity.
  • Live attenuated vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely)

  • Systemic corticosteroids: may diminish therapeutic effect.
  • Immunosuppressive agents: monitor for reduced efficacy.
  • Antibiotics for severe infections: watch for overlapping immune effects.

Frequently Asked Questions

Keytruda (pembrolizumab) is indicated for several advanced cancers, including melanoma, non‑small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, gastric cancer, cervical cancer, and tumors with high microsatellite instability or mismatch repair deficiency.

Pembrolizumab is a monoclonal antibody that binds to the PD‑1 receptor on T cells, preventing its interaction with PD‑L1 and PD‑L2. This blockade releases the inhibitory checkpoint, allowing the immune system to recognize and destroy cancer cells more effectively.

The dosing regimen for Keytruda is individualized by the prescribing oncologist based on the specific indication, patient weight, and clinical response. Healthcare providers determine the appropriate infusion schedule and amount for each patient.

Safety data for pembrolizumab in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and the drug may cross the placenta. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician.

To request Keytruda, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Keytruda and other PD‑1 inhibitors such as nivolumab share a similar mechanism of blocking the PD‑1 pathway. Clinical differences may arise in approved indications, dosing intervals, and specific trial outcomes, but overall efficacy and safety profiles are comparable across the class.

Keytruda must be stored refrigerated at 2‑8 °C (36‑46 °F). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Once prepared for infusion, it should be used within the time frame specified by the manufacturer.

Keytruda is given as an intravenous infusion. The infusion is typically administered over 30 minutes, although the exact duration may vary based on the dose and patient tolerance. Infusions are performed in a clinical setting where patients can be monitored for reactions.

The most serious risks include immune‑mediated adverse events such as pneumonitis, colitis, hepatitis, endocrinopathies (e.g., thyroiditis, adrenal insufficiency), nephritis, and severe skin reactions. Prompt recognition and management of these events are essential to minimize morbidity.

Keytruda is contraindicated in patients with known hypersensitivity to pembrolizumab or any of its excipients. It should also be avoided in individuals with active autoimmune diseases requiring systemic immunosuppression, those receiving live vaccines, or patients who have had organ transplants due to heightened risk of rejection.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Pembrolizumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT